hMAO-B-IN-2 (compound 6j) is an orally bioactive, selective, BBB (blood-brain barrier) penetrating and competitive reversible inhibitor of hMAO-B with IC50 of 4 nM. hMAO-B-IN-2 has low toxicity to SH-SY5Y cells and has good neuro-protective (neuro-protection) effect. hMAO-B-IN-2 could be used to study Alzheimer's disease (AD). hMAO-B-IN-2 is a reagent for click chemistry. It has Alkyne groups and could undergo CuAAc (copper-catalyzed azide-alkyne cycloaddition reaction) with compounds bearing Azide groups.

Physicochemical Properties

Molecular Formula	C18H23NO3
Molecular Weight	301.380125284195
Exact Mass	301.167
CAS #	2454459-87-9
PubChem CID	162671381
Appearance	Typically exists as solid at room temperature
LogP	2.6
Hydrogen Bond Donor Count	0
Hydrogen Bond Acceptor Count	4
Rotatable Bond Count	8
Heavy Atom Count	22
Complexity	400
Defined Atom Stereocenter Count	0
InChi Key	CLKPCTKGZGRHKG-UHFFFAOYSA-N
InChi Code	InChI=1S/C18H23NO3/c1-3-10-19(2)11-5-4-6-12-21-15-7-8-16-17(20)9-13-22-18(16)14-15/h1,7-8,14H,4-6,9-13H2,2H3
Chemical Name	7-[5-[methyl(prop-2-ynyl)amino]pentoxy]-2,3-dihydrochromen-4-one
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

ln Vitro	hMAO-B-IN-2 (compound 6j) exhibited strong inhibitory effects over a 15-minute period at IC50 values of 4. nM for hMAO-B and 6.04 nM for hMAO-A [1]. A reversible MAO-B inhibitor is called hMAO-B-IN-2 (30 min). Compound 6j restored the MAO-B enzyme activity to approximately 82% and 45%, respectively, after being diluted to 0.1 × IC50 and 1 × 50[1]. Significant inhibitory activity against MAO-B and good inhibitory performance against Aβ auto-induced aggregation (40.78 ± 6.27%) are demonstrated by hMAO-B-IN-2 (25 μM, 48 h)[1]. At a dose of 25 μM, hMAO-B-IN-2 (0-100 μM, 24 hours) does not appear to be hazardous [1]. In a dose-dependent manner, hMAO-B-IN-2 (0-25 μM, 24 hours) enhances cell survival and possesses neuroprotective properties against neurodegenerative disorders [
ln Vivo	The pharmacokinetic properties of hMAO-B-IN-2 (Compound 6j) (Sprague-Dawley rats; 3 mg/kg IV; 10 mg/kg PO; once) are deemed acceptable [1]. Male Sprague-Dawley rats' hMAO-B-IN-2 pharmacokinetic parameters [1]. AUC0-inf (μg/ L*h) 247.74 ± 11.48 268.49 ± 69.72 CL (L/h/kg) 3.33 ± 0.15 F (%) 36.10% Parameter IV (3 mg/kg) PO (10 mg/kg) T1/2 (h) 1.02 ± 0.17 1.33 ± 0.16 Tmax (h) 0.3 Cmax (μg/L) 639.29 ± 89.06 142.17 ± 72.21
Cell Assay	Cytotoxicity assay Cell Types: SH-SY5Y neuroblastoma cells [1] Tested Concentrations: 0, 6.25, 12.5, 25, 50, 100 μM Incubation Duration: 24 h Experimental Results: No toxicity was shown at 25 μM concentration.
Animal Protocol	Animal/Disease Models: SD (SD (Sprague-Dawley)) rat (male, 220±20 g) [1] Doses: 3 mg /kg (IV), 10 mg/kg (PO) Route of Administration: IV, PO (pharmacokinetic/PK/PK analysis) Experimental Results: Has acceptable pharmacokinetic/PK/PK properties and exhibits high maximum concentration, appropriate Half-life and good oral bioavailability.
References	[1]. Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-β aggregation against Alzheimer's disease. Eur J Med Chem. 2020;202:112475.

Solubility Data

Solubility (In Vitro)

May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples

Solubility (In Vivo)

Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	3.3181 mL	16.5904 mL	33.1807 mL
	5 mM	0.6636 mL	3.3181 mL	6.6361 mL
	10 mM	0.3318 mL	1.6590 mL	3.3181 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.